Literature DB >> 23242135

Discovery of indolyl acrylamide derivatives as human diacylglycerol acyltransferase-2 selective inhibitors.

Kyeong Lee1, Minkyoung Kim, Boah Lee, Jail Goo, Jiyoung Kim, Ravi Naik, Jee Hee Seo, Mun Ock Kim, Youngjoo Byun, Gyu-Yong Song, Hyun Sun Lee, Yongseok Choi.   

Abstract

A series of indolyl acrylamide derivatives was synthesized as potential diacylglycerol acyltransferase (DGAT) inhibitors. Furfurylamine containing indolyl acrylamide derivative 5h exhibited the most potent DGAT inhibitory activity using microsomes prepared from rat liver. Further evaluation against human DGAT-1 and DGAT-2 identified indolyl acrylamide analogues as selective inhibitors against human DGAT-2. In addition, the most potent compound 5h inhibited triglyceride synthesis dose-dependently in HepG2 cell lines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242135     DOI: 10.1039/c2ob27114a

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  3 in total

Review 1.  Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.

Authors:  Giovanni Musso; Maurizio Cassader; Roberto Gambino
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

2.  Suppression of Hepatitis C Virus Genome Replication and Particle Production by a Novel Diacylglycerol Acyltransferases Inhibitor.

Authors:  Dahee Kim; Ja-Il Goo; Mi Il Kim; Sung-Jin Lee; Moonju Choi; Thoa Thi Than; Phuong Hong Nguyen; Marc P Windisch; Kyeong Lee; Yongseok Choi; Choongho Lee
Journal:  Molecules       Date:  2018-08-20       Impact factor: 4.411

3.  Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile.

Authors:  K Futatsugi; K Huard; D W Kung; J C Pettersen; D A Flynn; J R Gosset; G E Aspnes; R J Barnes; S Cabral; M S Dowling; D P Fernando; T C Goosen; W P Gorczyca; D Hepworth; M Herr; S Lavergne; Q Li; M Niosi; S T M Orr; I D Pardo; S M Perez; J Purkal; T J Schmahai; N Shirai; A M Shoieb; J Zhou; B Goodwin
Journal:  Medchemcomm       Date:  2016-11-22       Impact factor: 3.597

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.